Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2001 1
2006 1
2015 1
2016 2
2019 1
2020 2
2021 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
Markers of activation of coagulation in cancer patients.
Stoencheva SS, Popov VG, Grudeva-Popova ZG, Deneva TI. Stoencheva SS, et al. Among authors: grudeva popova zg. Bratisl Lek Listy. 2023;124(1):29-35. doi: 10.4149/BLL_2023_004. Bratisl Lek Listy. 2023. PMID: 36519604
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Pour L, Szarejko M, Bila J, Schjesvold FH, Spicka I, Maisnar V, Jurczyszyn A, Grudeva-Popova Z, Hájek R, Usenko G, Thuresson M, Norin S, Jarefors S, Bakker NA, Richardson PG, Mateos MV. Pour L, et al. Among authors: grudeva popova z. Haematologica. 2024 Mar 1;109(3):895-905. doi: 10.3324/haematol.2023.283509. Haematologica. 2024. PMID: 37646660 Free PMC article. Clinical Trial.
Autoimmune Phenomena in Patients with Solid Tumors.
Nenova IS, Valcheva MY, Beleva EA, Tumbeva DY, Yaneva MP, Rancheva EL, Grudeva-Popova ZG. Nenova IS, et al. Among authors: grudeva popova zg. Folia Med (Plovdiv). 2016 Sep 1;58(3):195-199. doi: 10.1515/folmed-2016-0026. Folia Med (Plovdiv). 2016. PMID: 27760006
17 results